A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18-64 Years in the United States.

IF 5.2 3区医学 Q1 IMMUNOLOGY

Vaccines Pub Date : 2024-10-26 DOI:10.3390/vaccines12111217

Myron J Levin, Neda Al Rawashdh, Liliane Mofor, Pablo Anaya, Richard M Zur, Emily B Kahn, Daniel Yu, Joaquin F Mould-Quevedo

{"title":"A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18-64 Years in the United States.","authors":"Myron J Levin, Neda Al Rawashdh, Liliane Mofor, Pablo Anaya, Richard M Zur, Emily B Kahn, Daniel Yu, Joaquin F Mould-Quevedo","doi":"10.3390/vaccines12111217","DOIUrl":null,"url":null,"abstract":"Background: This analysis compares the cost-effectiveness of a cell-based influenza vaccine to a recombinant influenza vaccine, and each to no vaccination. The analysis is based on United States (US) commercial and societal perspectives.Methods: A Susceptible-Exposed-Infectious-Recovered (SEIR) transmission model of the total US population followed with a cost-effectiveness model for 18-64-year-olds was used to estimate the clinical and economic impact of vaccination over one influenza season (2018-2019). Deterministic and probabilistic sensitivity analyses were conducted.Results: Both enhanced vaccines prevented a substantial number of influenza cases and influenza-related deaths compared to no vaccination. The cell-based vaccine was associated with higher quality-adjusted life years (QALYs) gained compared to the recombinant vaccine or no vaccination. The cell-based vaccine had a 36% lower vaccination cost, amounting to $2.8 billion in cost savings, compared to the recombinant vaccine. The incremental cost-effectiveness ratios (ICERs) for the cell-based vaccine, compared to the recombinant vaccine or no vaccination, were dominant from all payer perspectives, regardless of risk groups.Conclusions: Overall, the cell-based vaccine was cost-saving compared to the recombinant vaccine for subjects aged 18-64 years in the US, achieving comparable health outcomes with a significant reduction in associated costs.","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"12 11","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11598601/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/vaccines12111217","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This analysis compares the cost-effectiveness of a cell-based influenza vaccine to a recombinant influenza vaccine, and each to no vaccination. The analysis is based on United States (US) commercial and societal perspectives.

Methods: A Susceptible-Exposed-Infectious-Recovered (SEIR) transmission model of the total US population followed with a cost-effectiveness model for 18-64-year-olds was used to estimate the clinical and economic impact of vaccination over one influenza season (2018-2019). Deterministic and probabilistic sensitivity analyses were conducted.

Results: Both enhanced vaccines prevented a substantial number of influenza cases and influenza-related deaths compared to no vaccination. The cell-based vaccine was associated with higher quality-adjusted life years (QALYs) gained compared to the recombinant vaccine or no vaccination. The cell-based vaccine had a 36% lower vaccination cost, amounting to $2.8 billion in cost savings, compared to the recombinant vaccine. The incremental cost-effectiveness ratios (ICERs) for the cell-based vaccine, compared to the recombinant vaccine or no vaccination, were dominant from all payer perspectives, regardless of risk groups.

Conclusions: Overall, the cell-based vaccine was cost-saving compared to the recombinant vaccine for subjects aged 18-64 years in the US, achieving comparable health outcomes with a significant reduction in associated costs.

查看原文本刊更多论文

美国 18-64 岁成人接种细胞型流感疫苗与重组流感疫苗的临床和经济比较。

背景：本分析比较了细胞型流感疫苗和重组流感疫苗以及不接种疫苗的成本效益。分析基于美国的商业和社会视角：方法：采用美国总人口的易感-暴露-感染-恢复（SEIR）传播模型以及 18-64 岁人群的成本效益模型来估算一个流感季节（2018-2019 年）内接种疫苗的临床和经济影响。对结果进行了确定性和概率敏感性分析：与不接种疫苗相比，两种强化疫苗都能预防大量流感病例和流感相关死亡。与重组疫苗或不接种疫苗相比，细胞基疫苗获得的质量调整生命年（QALYs）更高。与重组疫苗相比，细胞基疫苗的接种成本低 36%，可节省 28 亿美元。与重组疫苗或不接种疫苗相比，细胞基疫苗的增量成本效益比（ICER）从所有支付方的角度来看都占优势，与风险组无关：总体而言，对于美国 18-64 岁的受试者来说，细胞基疫苗比重组疫苗更节约成本，在实现可比健康结果的同时显著降低了相关成本。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccines Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

8.90

自引率

16.70%

发文量

1853

审稿时长

18.06 days

期刊介绍： Vaccines (ISSN 2076-393X) is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. Vaccines publishes high quality reviews, regular research papers, communications and case reports.